The Food and Drug Administration has cleared a new breast cancer pill from Roche, kicking off the launch of a medication the Swiss pharmaceutical giant expects to eventually become its best-selling product.
Roche said Monday that U.S. regulators approved its pill, which will be sold under the brand name Wilserdly, as part of a two-drug oral regimen for certain adults with ER-positive, HER2-negative breast cancer. Treatment is specifically indicated for people who’ve relapsed during or after hormone therapy in the post-surgery “adjuvant” setting. It’s also available following hormone therapy in those with metastatic disease. Only patients with mutations to a gene called ESR1 are eligible.
The clearance came about a month ahead of a Dec. 18 decision deadline. By Nov. 30 the company may receive a second FDA nod, in an earlier setting, that would significantly expand access to treatment.
The drug has a list price of $22,500 per month, comparable to similar breast cancer medicines, according to a Monday research note from analysts at RBC Capital Markets. Roche didn’t immediately respond to a request for comment.
Wilserdly is part of a newer class of oral medications known as “selective estrogen receptor degraders,” or SERDs. Drugmakers have long seen these treatments as valuable additions to breast cancer care, potentially supplanting a decades-old, injectable hormone therapy known as fulvestrant.
So far, though, the sales outlook for oral SERDs is unclear. Several from drugmakers such as Eli Lilly, AstraZeneca and now Roche are available. However, all of them are only cleared for patients with ESR1 mutations. And a few, including Roche’s drug, have failed clinical trials testing their use in the first-line setting.
“The key debate is not whether oral SERDs work, it's where they fit,” Jefferies analyst Michael Leuchten wrote to clients in an October note.
Roche believes Wilserdly could be different, and has been adamant that the drug could become its top-selling product. One reason is that, unlike some of its competitors, Roche has seen its drug succeed in multiple treatment lines. The approval issued Monday covers use in a setting where other oral SERDs are available. But Wilserdly is the only member of its class as of yet to also prove beneficial in the adjuvant setting.
On a July conference call with analysts, Roche Pharmaceuticals head Teresa Graham said that the data Roche has accumulated to date suggests it has “about 80% of the market covered.” RBC analyst Trung Huynh has been similarly optimistic, estimating earlier this year that Wilserdly could generate as much as $14 billion in peak annual sales — much of which would come from earlier-line use.
Leuchten is less sure. In October, he noted how projections for oral SERDs in the adjuvant setting could depend on how much “white space” remains after the expansion of other drugs known as CDK 4/6 inhibitors. The remaining opportunity “remains substantial, though likely narrower and more segmented than headline patient numbers imply,” he wrote.
For now, Wilserdly will compete for share in more advanced disease. Notably, its prescribing information carried warnings for a slow resting heart rate and potential damage to a developing fetus. Those disclosures “were not expected,” but the lack of a heart monitoring requirement still gives Wilserdly a potential edge over AstraZeneca’s drug, wrote RBC analyst Huynh.
Monday’s approval is “a key first step” for Roche, he added.